A Vascular Modulator, Hepatocyte Growth Factor, Is Associated With Systolic Pressure

Yoshio Nakamura(Tokyo Institute of Technology), Toshio Ogihara(Osaka University), Motokuni Aoki(Osaka City University), Toshikazu Nakamura(The University of Osaka), Shigefumi Nakamura(The University of Osaka), Atsushi Moriguchi(The University of Osaka), Kunio Matsumoto(Kanazawa University), Jitsuo Higaki(Saiseikai Matsuyama Hospital), Ryuichi Morishita(The University of Osaka)
Hypertension
September 1, 1996
10.1161/01.hyp.28.3.409
Cited by 138

Related Papers

Erratum: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
|Hypertension Research|2014|1.4k
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
|The Lancet|2021|997
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction
|Nature Medicine|1997|589
Hepatocyte growth factor gene therapy of liver cirrhosis in rats
|Nature Medicine|1999|588